IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
-4.43%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$307M
AUM Growth
-$43.3M
(-12%)
Cap. Flow
+$19.6M
Cap. Flow
% of AUM
6.4%
Top 10 Holdings %
Top 10 Hldgs %
39.15%
Holding
181
New
26
Increased
23
Reduced
31
Closed
32
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Akero Therapeutics
AKRO
|
$9.92M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.62M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$8.53M |
| 5 |
Vaxcyte
PCVX
|
$7.55M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$6.57M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$6.3M |
| 3 |
Avalo Therapeutics
AVTX
|
$6.17M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$4.91M |
| 5 |
BridgeBio Pharma
BBIO
|
$4.32M |
Sector Composition
| 1 | Healthcare | 95.44% |
| 2 | Consumer Staples | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTSR
26
Metsera, Inc. Common Stock
MTSR
$3.81B
| $4.08M | 0.5% |
+150,000
| New | +$4.08M |
|
27
Neuronetics
STIM
$210M
| $4.05M | 0.5% |
+1,100,000
| New | +$4.05M |
|
28
Dyne Therapeutics
DYN
$1.94B
| $3.75M | 0.46% |
+358,837
| New | +$3.75M |
|
29
Trevi Therapeutics
TRVI
$905M
| $3.62M | 0.45% |
575,000
+250,000
| +77% | +$1.57M |
|
|
MAZE
30
Maze Therapeutics, Inc. Common Stock
MAZE
$692M
| $3.55M | 0.44% |
+322,740
| New | +$3.55M |
|
31
Janux Therapeutics
JANX
$1.5B
| $3.5M | 0.43% |
129,691
+55,000
| +74% | +$1.49M |
|
32
Eledon Pharmaceuticals
ELDN
$156M
| $3.48M | 0.43% |
1,025,221
-101,416
| -9% | -$344K |
|
|
33
BridgeBio Pharma
BBIO
$10.3B
| $3.14M | 0.39% |
90,837
-124,876
| -58% | -$4.32M |
|
34
Cumberland Pharmaceuticals
CPIX
$50.7M
| $3.13M | 0.39% |
+740,000
| New | +$3.13M |
|
35
Keros Therapeutics
KROS
$630M
| $2.79M | 0.34% |
+274,009
| New | +$2.79M |
|
36
Abeona Therapeutics
ABEO
$353M
| $2.54M | 0.31% |
533,581
| – | – |
|
|
CYBN
37
Cybin
CYBN
$154M
| $2.52M | 0.31% |
397,175
| – | – |
|
38
iBio
IBIO
$16.7M
| $2.41M | 0.3% |
599,913
| – | – |
|
|
DRUG
39
Bright Minds Biosciences
DRUG
$296M
| $2.36M | 0.29% |
65,431
-86,780
| -57% | -$3.13M |
|
40
Evolus
EOLS
$497M
| $2.32M | 0.29% |
193,265
-180,000
| -48% | -$2.17M |
|
41
Relay Therapeutics
RLAY
$684M
| $1.95M | 0.24% |
743,308
+50,000
| +7% | +$131K |
|
42
Lexeo Therapeutics
LXEO
$282M
| $1.91M | 0.24% |
550,029
+50,728
| +10% | +$176K |
|
43
Arcturus Therapeutics
ARCT
$480M
| $1.85M | 0.23% |
175,000
-25,000
| -13% | -$265K |
|
44
Kodiak Sciences
KOD
$536M
| $1.82M | 0.22% |
649,534
+73,368
| +13% | +$206K |
|
|
ORKA
45
Oruka Therapeutics, Inc. Common Stock
ORKA
$587M
| $1.8M | 0.22% |
+175,000
| New | +$1.8M |
|
46
Apellis Pharmaceuticals
APLS
$3.47B
| $1.64M | 0.2% |
75,000
+71,406
| +1,987% | +$1.56M |
|
|
VERV
47
DELISTED
Verve Therapeutics
VERV
| $1.64M | 0.2% |
358,393
+188,402
| +111% | +$861K |
|
48
Arvinas
ARVN
$593M
| $1.61M | 0.2% |
+229,900
| New | +$1.61M |
|
|
49
Avalo Therapeutics
AVTX
$151M
| $1.6M | 0.2% |
200,000
-770,259
| -79% | -$6.17M |
|
50
VistaGen Therapeutics
VTGN
$110M
| $1.5M | 0.19% |
601,703
+524,087
| +675% | +$1.31M |
|